| [1] |
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase Ⅲ NALA Trial[J]. J Clin Oncol, 2020，38(27):3138-3149.
|
| [2] |
Qamar J, O’Dea A, Bardia A, et al. Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (feline trial)[J]. J Clin Oncol, 2020，38(suppl 15): 505.
|
| [3] |
Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2021，22(2):212-222.
|
| [4] |
Loibl SMF, Martin M. Abstract GS1-02: Phase Ⅲ study of Palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B[J]．Cancer Res，2021，81 (Suppl 4): GS1-02.
|
| [5] |
O’Shaughnessy JA, Johnston S, Harbeck N, et al. Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer[EB/OL]. (2020-12-02)[2021-02-20]．
URL
|
| [6] |
Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol，2020，31(3):377-386.
|
| [7] |
André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021，32(2):208-217.
|
| [8] |
Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase Ⅲ SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer[J]. Ann Oncol, 2020，31(8):1001-1010.
|
| [9] |
Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial[J]. J Clin Oncol, 2020，38(5):423-433.
|
| [10] |
Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus Capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2020，21(3):345-357.
|
| [11] |
Lee S, Martine P, Hope S, et al. Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-，hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane[C].2020 San Antonio Breast Cancer Virtual Symposium, Texas, USA, 2020. New York：Springer，2020.
|
| [12] |
Sabnis GJ, Goloubeva OG, Kazi AA et al. HDAC inhibitor entinostat restores responsiveness of Letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2[J]. Mol Cancer Ther, 2013，12(12):2804-2816.
|
| [13] |
Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer[J]. Future Oncol, 2017，13(13):1137-1148.
|
| [14] |
Yeruva SLH, Zhao F, Miller KD, et al. E2112: randomized phase iii trial of endocrine therapy plus Entinostat/placebo in patients with hormone receptor-positive advanced breast cancer[J]. NPJ Breast Cancer, 2018，4:1.
|
| [15] |
Conte P, Schneeweiss A, Loibl S, et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant Trastuzumab Emtansine versus Trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer[J]. Cancer, 2020，126(13):3132-3139.
|
| [16] |
Nadia H, Seock-Ah I, Carlos H, et al. Primary analysis of KAITLIN: A phase Ⅲ study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC)[J]. J Clin Oncol, 2020，38(suppl 15):500.
|
| [17] |
van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without Anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018，19(12):1630-1640.
|
| [18] |
Pérez-García, José Manuel, Gebhart G, et al. Chemotherapy de-escalation using an 18F-FDG PET/CT-based, pathologic response-adapted strategy in HER2-positive early breast cancer: The PHERGain Trial[EB/OL]. (2020-12-02)[2021-02-20]．
URL
|
| [19] |
Curigliano G, Murthy R, Loi S, et al. Tucatinib vs placebo added to Trastuzumab and Capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)[J]. Ann Oncol, 2020，31(suppl 2):S62-S63.
|
| [20] |
Modi S, Saura C, Yamashita T, et al. Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer[C].2020 San Antonio Breast Cancer Virtual Symposium, Texas, 2020.
|
| [21] |
Coughlin SS. Epidemiology of breast cancer in women[EB/OL]. [2021-02-20].
URL
|
| [22] |
Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors[J]. Drugs Today (Barc), 2019，55(9):575-585.
|
| [23] |
Perrone E, Manara P, Lopez S, et al. Sacituzumab Govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo[J]. Mol Oncol, 2020，14(3):645-656.
|
| [24] |
Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer[J]. Ann Oncol，2010，21(5):961-967.
|
| [25] |
Cardillo TM, Rossi DL, Zalath MB, et al. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer[J]. Oncotarget, 2020，11(43):3849-3862.
|
| [26] |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019，380(7):617-628.
|
| [27] |
Iwata H, Emens L, Adams S, et al. 49MO IMpassion130: Final OS analysis from the pivotal phase Ⅲ study of atezolizumab + nab-paclitaxel vs placebo + Nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020，31(suppl 6):S1261-s1262.
|
| [28] |
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment[J]. Cancer Discov, 2019，9(2):176-198.
|
| [29] |
Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies？[J]. Expert Rev Anticancer Ther, 2015，15(1):51-68.
|
| [30] |
Dylann CE. Investigators tailor TNBC therapy using genomic alterations[EB/OL]. (2020-10-22)[2021-02-20]．
URL
|
| [31] |
Bardia A, Tolaney SM, Loirat D, et al. LBA17 ASCENT: A randomized phase Ⅲ study of Sacituzumab Govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)[J]．Ann Oncol, 2020，31(suppl 4):S1149.
|
| [32] |
Kim SB, Dent R, Im SA，et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol，18(10):1360-1372.
|
| [33] |
Schmid P, Cortes J, Robson ME, et al.A phase Ⅲ trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290)[J]. J Clin Oncol, 2020，38(suppl 15):TPS1109.
|
| [34] |
Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination-related genes[J]. J Clin Oncol, 2020，38(36):4274-4282.
|